Allergy Therapeutics Plc has received a public opening position disclosure/dealing disclosure from Cavendish Securities Plc, an exempt principal trader. The disclosure is made in accordance with Rule 8.5 of the Takeover Code. Cavendish Securities Plc is connected to Allergy Therapeutics Plc, the offeror/offeree in question. The date of the position held/dealing undertaken is 21/09/2023.

In terms of positions, Cavendish Securities Plc owns and/or controls 193,721 relevant securities of Allergy Therapeutics Plc, which represents 0.03% of the total. There are no cash-settled derivatives or stock-settled derivatives (including options) and agreements to purchase/sell.

The disclosure also includes information on dealings by Cavendish Securities Plc. They have made purchases of 5,651 securities of Allergy Therapeutics Plc at a highest price per unit of 2.50 and a lowest price per unit of 2.50. There are no cash-settled derivative transactions, stock-settled derivative transactions, or other dealings.

There are no indemnity or other dealing arrangements, agreements, arrangements, or understandings relating to options or derivatives. No supplemental form 8 (open positions) is attached to the disclosure.

The contact name for further information is Jennifer O'Donnell, and the telephone number is 020 7220 0500. The disclosure was made on 22/09/2023.